Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Herz 1997 ; 22 Suppl 1 (ä): 51-5 Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Einfluss von Magnesium auf anhaltende ventrikulare Tachykardien #MMPMID9333592
Manz M; Jung W; Luderitz B
Herz 1997[Jun]; 22 Suppl 1 (ä): 51-5 PMID9333592show ga
Intravenous application of magnesium was suggested for the management of persistent ventricular tachycardia. In patients with torsade de pointes tachycardia the injection of magnesium controlled the life threatening arrhythmias reliably, thus magnesium became the treatment of choice in this setting. The results in patients with persistent monomorphic ventricular tachycardia are controversial. In one study, ventricular tachycardias could be controlled in 8 of 10 patients by 2,000 mg magnesium sulfate. In a randomized trial with 43 patients, termination of the ventricular tachycardia could be accomplished in 6 of 20 patients under the influence of 4,000 mg magnesium sulfate, whereas 3 of 24 patients exhibited termination of the tachycardia following placebo; the difference did not reach statistical significance. In our study 4 patients with torsade de pointes tachycardia could be controlled by the application of magnesium glutamate (2 x 1,000 mg intravenously). Of 25 patients with persistent monomorphic ventricular tachycardia, the arrhythmia ended in 8 patients under the influence of magnesium. No significant change of the RR intervals and the QRS duration during ventricular tachycardia could be demonstrated following magnesium injection. Cardiac index during ventricular tachycardia increased from 2.0 +/- 0.6 l/min x m2 to 2.5 +/- 0.1 l/min x m2 (p < 0.05). In a further investigation the dose of magnesium was increased to 2 x 9 mmol. To detect possible interactions with antiarrhythmic agent, 10 patients under chronic antiarrhythmic therapy with class-III-agents were compared with 10 patients without such treatment. Plasma levels of magnesium increased from 0.79 +/- 0.1 mmol/l to 1.87 +/- 0.5 mmol/l. In 5 of the 20 patients ventricular tachycardia ended under the influence of magnesium: 2 patients were on chronic antiarrhythmic agents, whereas 3 had no chronic therapy. There were no significant differences in the RR intervals and the duration of the monophasic action potentials during the ventricular tachycardia under the influence of magnesium. These data indicate that the bolus therapy of magnesium controls persistent monomorphic ventricular tachycardia in a minority of patients only. Therefore, magnesium injection cannot be recommended for treatment of monomorphic ventricular tachycardia in the emergency setting. On the other hand, magnesium application can be considered the therapy of choice for patients with torsade de pointes tachycardia.
Herz 1997 ; 22 Suppl 1 (ä): 51-5
